RNA viruses generally are benign in...

RNA viruses generally are benign in the early stage of infection, on the other hand they have the potential to induce acute respiratory distress syndrome if they spread to the lower respiratory tract or progres to pneumonia. Antiviral unsalable articles can be used to treat and stop these infections, although they are not a substitute for vaccine. Part II of this article focuses forward antiviral agents used in the management of influenza and respiratory syncytial virus (RSV)

Influenza Viruses

Antiviral physics that prevent and treat influenza should be considered adjuncts to vaccine--not substitutes. Traditionally, amantadine (Symmetrel) and, to a smaller extent, rimantadine (Flumadine) have been used for preventing and treating influenza protoplast A (Table 1). (1-4) However, in 1999 couple drugs that effectively treat and preclude influenza types A and B were introduced. These medicines zanamivir (Relenza) and oseltamivir (Tamiflu), provide more thorough coverage when the type of influenza is unknown (Table 2) (1-4)

INFLUENZA archetype A

Amantadine and Rimantadine. Amantadine was the first medicine approved for prophylaxis of influenza adumbration A (in 1966), and in 1976 it was approved for treatment and prophylaxis in adults and children older than single in kind year. Rimantadine became available in 1993 for treatment and prophylaxis of influenza mark A in adults and for prophylaxis in children. Neither of these medicines is effective against influenza original B.

Treatment usually is continued for three to five days or discontinued 24 to 48 hours following resolution of symptoms. The efficacy of the two drugs is similar, and the average duration of illness is shortened by the agency of approximately one day. (5)

These physics can be used for prophylaxis in high-risk patients (Table 3) (6) and for influenza-related complications if an outbreak of influenza appears within two weeks following vaccination. (4) In a newly come review, the average effectiveness of amantadine and rimantadine for the prevention of influenza was 61 and 72 percent respectively. (7)

Although amantadine is considerably les expensive than rimantadine, it crosse the blood-brain barrier and appears to cause more central nervous hypothesis side effects, including dizziness, ataxia, hallucinations, agitation, and confusion. This is especially genuine in elderly patients and may be associated with higher serum concentrations. A split dosage may help minimize adverse events

Amantadine is primarily eliminated in the kidneys as unchanged drug; therefore, the dosage must be modified in somewhat old patients and patients with reduc renal function (Table 4) (8)

Rimantadine's adverse drug-reaction profile is similar to that of amantadine with consider to gastrointestinal side effects of the like kind as nausea, vomiting, and dyspepsia, if it be not that rimantadine appears to cause fewer central nervous order side effects. (9)

Oseltamivir and Zanamivir. Oseltamivir, which is taken orally, was approved for prophylaxis of influenza in late 2000 and zanamivir's approval for prophylaxis is pending. They are equally effective in reducing symptoms and duration of illness when taken within 48 hours of the attack of symptoms. (10-14)

Zanamivir is inhaled and requires the use of an inhalation device, which may be difficult for somewhat old patients to use. Because of its potential to induce bronchospasm and model lung function, use of zanamivir generally should be avoided in patients with asthma and chronic obstructive pulmonary disease.

INFLUENZA impressed sign B

Oseltamivir and zanamivir are first-line choices for prevention and treatment of infection during outbreaks of influenza token B.

Respiratory Syncytial Virus (RSV)

RSV is a every-day cause of bronchiolitis in children. Treatment consists primarily of supportive care with fluids, oxygen and aerosolized bronchodilators.

Ribavirin. In a fix upon group of high-risk infants (premature infants younger than 36 weeks and infants with bronchopulmonary dysplasia, congenital heart disease, or immunodeficiency) with strait-laced infections, aerosolized ribavirin (Virazole) has been used. (15) The use of this put drugs into requires special equipment and adroit respiratory monitoring. It is expensive, with a price exceeding $1,000 per day.

RSV Immune Globulin and Palivizumab. In high-risk patients, prophylaxis against RSV should be considered. During the winter month monthly administration of intravenous RSV immune globulin (RespiGam) or intramuscular palivizumab (Synagis) may decrease the number of RSV episodes. Because of increased morbidity, RSV immune globulin should not be given to patients with congenital heart disease.